Beijing Hotgen Biotech Co

Beijing Hotgen Biotech Co Net Margin

The Net Profit Margin of Beijing Hotgen Biotech Co (688068.SS) as of Nov 5, 2026 is -51.64 %. In the previous year, Net Profit Margin was -37.39 % — a change of 38.12% (lower).

Net Margin

-51.64 %

YoY

38.12%

Last updated:

Net Profit Margin of Beijing Hotgen Biotech Co is 2025 -51.64 % . Net Profit Margin of Beijing Hotgen Biotech Co was 2024 -37.39 % . It decreases by 38.12% lower compared to the previous year.

Beijing Hotgen Biotech Co's net margin stands at -51.6%, down from 40.7% several years earlier.

The Beijing Hotgen Biotech Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
25.73 CNY
Jan 1, 2019
16.10 CNY
Jan 1, 2020
21.82 CNY
Jan 1, 2021
40.71 CNY
Jan 1, 2022
26.56 CNY
Jan 1, 2023
5.28 CNY
Jan 1, 2024
-37.39 CNY
Jan 1, 2025
-51.64 CNY
The Beijing Hotgen Biotech Co Net Margin history
YEARNet MarginYoY
-51.64 %+38.12%
-37.39 %-808.15%
5.28 %-80.13%
26.56 %-34.75%
40.71 %+86.55%
21.82 %+35.54%
16.10 %-37.42%
25.73 %+21.56%
21.16 %-10.20%
23.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Beijing Hotgen Biotech Co Stock analysis

What does Beijing Hotgen Biotech Co do? Beijing Hotgen Biotech Co., Ltd. generates revenue through the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The firm's product portfolio primarily consists of in vitro diagnostic reagents, in vitro diagnostic instruments, and biological raw materials. These offerings are designed to address clinical needs in areas such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections. Additionally, the products serve public safety applications including biosafety, food safety, and disease control and emergency response. The company operates in both domestic and overseas markets, selling its solutions to entities involved in clinical healthcare and public safety sectors. By providing specialized diagnostic tools and biological materials, Beijing Hotgen Biotech Co., Ltd. supports medical diagnosis and emergency response efforts globally. The business model relies on the direct sale of these manufactured goods to customers who require advanced diagnostic capabilities for disease detection and safety monitoring. Beijing Hotgen Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beijing Hotgen Biotech Co stock

Net Profit Margin of Beijing Hotgen Biotech Co is -51.64 % in 2025.

Net Profit Margin of Beijing Hotgen Biotech Co changed from -37.39 % to -51.64 %, representing a 38.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Beijing Hotgen Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Beijing Hotgen Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Beijing Hotgen Biotech Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Beijing Hotgen Biotech Co